EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY 3.0

Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis

Shuheng Yang, Yadong Zhou, Lei Zeng

Advances in Clinical and Experimental Medicine · 2023

DOI: 10.17219/acem/158488 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Advances in Clinical and Experimental Medicine, 2023. Verfasst von Shuheng Yang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Chongqing University Fuling Hospital, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansSorafenibNivolumabPhenylurea CompoundsPyridines

Stichwörter der Autor:innen

hepatocellular carcinomameta-analysisnivolumabregorafenibsorafenib

Substanzen

SorafenibNivolumabregorafenibPhenylurea CompoundsPyridines

Autor:innen und Institutionen

  • Department of Hepatobiliary Surgery, Chongqing University Fuling Hospital, China.
  • Department of Hepatobiliary and Pancreatic Surgery, Third Affiliated Hospital of Chongqing Medical University, China.

Zitieren

APA

Yang, S., Zhou, Y., & Zeng, L. (2023). Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Advances in Clinical and Experimental Medicine. https://doi.org/10.17219/acem/158488

Vancouver

Yang S, Zhou Y, Zeng L. Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis. Advances in Clinical and Experimental Medicine. 2023. doi:10.17219/acem/158488

BibTeX
@article{Yang2023,
  author = {Yang, Shuheng and Zhou, Yadong and Zeng, Lei},
  title = {Regorafenib compared to nivolumab after sorafenib failure in patients with hepatocellular carcinoma: A systematic review and meta-analysis},
  journal = {Advances in Clinical and Experimental Medicine},
  year = {2023},
  doi = {10.17219/acem/158488}
}
Kostenlos starten →